

Inflammatory Bowel Disease: Percentage of patients diagnosed with extensive mild-moderate ulcerative colitis that receive a high-(> 3 g/d) or standard-dose mesalamine (2-3 g/d) or diazo-bonded 5-aminosalicylate (5-ASA) rather than low dose mesalamine (< 2 g/d), sulfasalazine or no treatment.

How to implement this AGA quality measure

Access AGA's quality measures at www.gastro.org/quality

